His factory for life science startups has launched more than 100 companies, including Moderna.See where Noubar Afeyan lands on the #Forbes250: America's Greatest Innovators list: https://t.co/CFs11UNXUH (Photo: Michael Prince for Forbes) https://t.co/1t8LkSokES ...

Darmstadt, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- Employee volunteer program brings hands-on science learning to communities worldwideMore than 600.000 students reached and nearly 200.000 employee volunteer hours Ambitious 2035 goals aim to double student reach and expand global impact Merck, a leading science and technology company, marks the 10th anniversary of SPARK™, its global employee volunteer program that connects employees with communities through hands-on science learning and local service ...

His factory for life science startups has launched more than 100 companies, including Moderna.See where Noubar Afeyan lands on the #Forbes250: America's Greatest Innovators list: https://t.co/CFs11UNXUH (Photo: Michael Prince for Forbes) https://t.co/Uw0xnWBwqB ...

His factory for life science startups has launched more than 100 companies, including Moderna.See where Noubar Afeyan lands on the #Forbes250: America's Greatest Innovators list: https://t.co/CFs11UNXUH (Photo: Michael Prince for Forbes) https://t.co/tpLldaWWTk ...

Core Insights - Diversified Healthcare Trust has successfully completed a strategic transformation, focusing on operational recovery and organic value creation through advanced CRM platforms and dynamic pricing [5][7]. Group 1: Q4 2025 Earnings Highlights - Achieved 31.3% consolidated NOI growth in 2025, driven by a 230 basis point expansion in SHOP margins and a 5.8% increase in average monthly rates [5]. - Executed $1.4 billion in capital markets activity, reducing leverage by over three turns and clearing all debt maturities until 2028 [5]. - Concluded a large-scale disposition program, selling 69 properties for $605 million to focus on core portfolio performance [5]. - SHOP occupancy reached 82.4% on a same-property basis, capitalizing on favorable demographic trends and muted new supply [5]. Group 2: 2026 Outlook and Growth Drivers - Projecting 2026 SHOP NOI between $175 million and $185 million, assuming approximately 300 basis points of average occupancy growth year-over-year [5]. - Anticipating a 4% to 6% rate growth range, primarily driven by legacy Aleris properties and outsized pushes at the beginning of the year [5]. - Planning a new ROI initiative to renovate closed skilled nursing wings into memory care units, potentially adding 500 units with mid-teens returns [5][7]. - Expecting recurring capital expenditures to decrease by over 18% at the midpoint to a range of $100 million to $115 million as portfolio upgrades stabilize [5]. Group 3: Structural Adjustments and Risk Factors - Medical Office and Life Science NOI is expected to decline in 2026 due to the sale of 31 properties that contributed $12.3 million in 2025 [5]. - Identified 3.9% of annualized revenue in the Medical Office portfolio expected to vacate in 2026, including two large single-tenant buildings [5]. - Transition of 116 communities created 'noisy' quarterly results, though management expects incremental benefits as new operators integrate business models [5].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 27-28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

As filed with the Securities and Exchange Commission on January 16, 2026. Registration No. 333-291993 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ______________________________ HELIX ACQUISITION CORP. III (Exact name of registrant as specified in its charter) ______________________________ | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdict ...

Core Viewpoint - Merck KGaA is positioning itself for a "next wave of growth" through three strategic pillars: Process Solutions in Life Science, rare diseases in Healthcare, and Semiconductor Solutions in Electronics, while reaffirming its 2025 guidance and outlining expectations for 2026 [4][7][8]. Group 1: Strategic Growth Pillars - The company operates across three main business segments: Healthcare, Life Science, and Electronics, focusing investments on these growth pillars [2][4]. - In Life Science, Merck emphasizes its leadership in bioprocessing within Process Solutions, highlighting strong growth momentum and stable long-term market fundamentals [2][3]. - The acquisition of SpringWorks is seen as a strategic move to bolster the rare diseases segment in Healthcare, which is now considered a new strategic pillar [2][6]. - In Electronics, Semiconductor Solutions accounts for approximately 80% of Electronics sales, positioning the company to benefit from AI-driven demand [5][17]. Group 2: Financial Guidance and Growth Expectations - Management confirmed its 2025 guidance, expecting mid-single-digit organic sales growth for the overall group and low double-digit growth from the three strategic pillars, which are projected to contribute over 80% of future growth [7][10]. - The company anticipates margin expansion of about 100 basis points, although this may be impacted by healthcare lifecycle effects in 2026 [7][10]. Group 3: Life Science Segment Insights - A new organizational design in Life Science was implemented to enhance customer interactions, structured around Process Solutions, Advanced Solutions, and Discovery Solutions [11]. - The Process Solutions segment is expected to be the primary growth engine, targeting around 10% organic growth over the midterm, driven by demand in both traditional and novel modalities [13]. - Near-term challenges are noted in lab-related businesses due to muted conditions in China and cautious purchasing behavior in the U.S. academic sector [13]. Group 4: Healthcare Segment Developments - The loss of exclusivity for Mavenclad in the U.S. presents a near-term headwind, but growth is expected to be driven by the rare disease franchise and fertility products like Pergoveris, which has shown a 20% compound annual growth rate outside the U.S., Japan, and China [6][16]. - Three priority products in the rare disease segment have a combined peak sales potential of approximately EUR 2.5 billion [6][15]. Group 5: Electronics Segment Dynamics - The shift towards advanced nodes in semiconductor solutions is highlighted, with more than 50% of Merck's semiconductor portfolio in advanced nodes compared to 33% in the broader market [5][17]. - Advanced packaging is identified as a significant growth area, with expectations of exceeding EUR 100 million in sales [5][19].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, specifically titled Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust (REIT) with a focus on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 27-28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million related to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

Market Overview - The market is experiencing a rally as the likelihood of a Federal Reserve rate cut increases, with December odds now at 70%, up from 33% [1] - The technology sector is showing positive momentum, supported by stronger earnings trends compared to the overall market [5] Sector Analysis - The healthcare sector is viewed as under-owned and priced for pessimism, having shown healthy earnings trends across various sub-sectors [6] - The technology sector has reset after a significant six-month rally, with some stocks experiencing a 40% decline since October highs [4] Investment Sentiment - There is a belief that the market is not priced for perfection, as some areas have become euphoric, but a reset has occurred [3] - The current market conditions are seen as favorable for continued growth, driven by earnings and advancements in productivity, particularly in AI [13] Future Outlook - The expectation is that the Federal Reserve will cut rates in the coming year, which will support higher earnings and market growth [10][14] - Historical trends suggest that November typically sees a bottom around November 20th, leading into a seasonal rally [11] Volatility and Risks - Recent volatility in stocks and Fed funds futures is noted, but it is suggested that the market will rally into December despite potential concerns [15][16] - The market has shifted expectations for a December rate cut to 80%, which could pose a risk if conditions change unexpectedly [15]